BAY 3630942 + BAY 3547922

This combination consists of **two monoclonal antibody preparations** under investigation in clinical trials for liver cancer and other selected solid cancers. - **BAY 3547922** is a monoclonal antibody-chelator conjugate that is not radiolabeled, intended as a pre-infusion to saturate or block peripheral targets and reduce off-target binding of subsequent radiolabeled antibody. - **BAY 3630942** is the same monoclonal antibody, conjugated with the radionuclide tracer zirconium-89 (^89Zr), allowing for imaging biodistribution, dosimetry, and tumor targeting by PET/CT. Both are designed to selectively bind a tumor-associated antigen, likely Glypican-3 (GPC3), to target hepatocellular carcinoma (HCC) and possibly other solid tumors expressing GPC3. In the referenced first-in-human phase 1 trial, BAY 3547922 is administered intravenously, followed by BAY 3630942, enabling researchers to map antibody pharmacokinetics and dosimetry and to model future targeted radionuclide therapies using the same antibody backbone. Neither compound is currently a therapeutic agent—BAY 3630942 in particular is used as a tracer, not for direct therapy—but this research informs subsequent therapeutic development for HCC and related cancers[1][3][5][6].

Other names

BAY 3630942BAY3630942BAY-3630942BAY 3547922BAY3547922BAY-3547922